Moreover, an IDO-derived peptide vaccine activates IDO-specific T cells which recognize and kill both tumor cells and immunosuppressive dendritic cells in vitro, significantly improving overall survival in III/IV NSCLC patients [157]. Here, IDO1 is linked to non-small cell lung carcinoma.